Your Health, We Care
Another NameHernix、LuciNera、Nerlynx、来那替尼
IndicationsIt is indicated for the treatment of early-stage and advanced-stage HER2-positive breast cancer, and can be used as a monotherapy for adjuvant treatment or in combination with capecitabine for metasta
Reg No.10 L 1225/24
Inspection NO.2563-24
This drug manufactured by Lucius Pharmaceuticals is a targeted therapy for HER2-positive breast cancer, with definite clinical efficacy, a standardized adverse reaction management plan, and favorable therapeutic cost-effectiveness.
Overview of Key Information for Neratinib.
The active ingredient is neratinib, with 40 mg per tablet.
For adult patients with HER2-positive breast cancer.
The recommended dosage is 240 mg (6 tablets) once daily, to be taken with meals. The specific treatment course shall be determined according to the patient’s condition.
Dosage adjustment is required for patients with severe hepatic impairment. This drug is contraindicated in pregnant women and lactating women.
There is no specific antidote for overdosage. Symptomatic and supportive treatments should be administered.
Store the medicine at room temperature and protect it from moisture.
Pharmacokinetic data indicate that its half-life is approximately 14.6 hours, and it is mainly metabolized in the liver.
FDA，2021.06
